Loading
A phase 1/2 trial of Pembrolizumab and Carboplatin in endometrial cancer and cervical cancer, run by NETRIS Pharma, active and no longer recruiting.
GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab is a phase 1/2 interventional study registered as NCT04652076 by NETRIS Pharma, with 240 participants enrolled, started 2020-12-14 and due to reach its primary completion in 2025-10-30. Interventions recorded: NP137, Pembrolizumab, Paclitaxel and Carboplatin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Advanced or recurrent endometrial cancer, Merck & Co. (MSD), Endometrial cancer, Carboplatin and the tag pipeline.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Platinum agents, Carboplatin and the tag pipeline.
Shares Merck & Co. (MSD), Endometrial cancer, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Platinum agents, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Platinum agents, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Carboplatin, Pembrolizumab, Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Carboplatin, Cytotoxic chemotherapy, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Endometrial cancer, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/